A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

L
Larry Cripe, MD

Primary Investigator

Overview

The purpose of this study is to see if we lower the chance of AML returning or getting worse by adding a new drug to the usual combination of drugs.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia
  • Age: Between 60 Years - 100 Years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Diagnosis of acute myeloid leukemia (AML) based on 2017 World Health Organization (WHO) criteria excluding acute promyelocytic leukemia with PML-RARA.
    Note: Patients with myeloid sarcoma without bone marrow involvement, acute leukemia of ambiguous lineage or blast transformation of chronic myelogenous leukemia (CML) are not eligible.
  • No evidence of central nervous system involvement of AML.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 20 Nov 2022. Study ID: 1904708908 (A041701)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center